StreetAlpha.app
Home › Stocks › CRVO

CervoMed Inc. (CRVO)

$1.46
▲ +9.77%
LAST CLOSE · NOV 20

CervoMed is a Boston biotechnology company developing neflamapimod, an oral drug candidate for age-related brain disorders. It last closed at $1.46 on Nov 20, up 9.77% on the day. The next earnings report for CRVO is expected around Tue, Mar 16, 2027, after the close. For the quarter ended Sep 2026, CRVO reported EPS of -$0.39 on revenue of $0, with revenue down 100.0% from a year ago. Over its last 8 reports the stock moved an average of 4.1% the session after earnings. Over the last 12 months CRVO insiders bought $3.2M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is CRVO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CRVO.

Key Stats

Last 12 months
Results
Revenue
$9K
−99.9% vs a year ago
Net income
−$28.5M
−326822.5% margin
EPS (diluted)
−$2.65
Operating margin
−334924.9%
−$29.2M operating income
Valuation
Market cap
$22.1M
15.1M shares
P/E
–
No P/E while losing money
Price to sales
2531.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$6.1M
At Sep 30
Shareholder equity
$17.4M
Shares outstanding
15.1M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $7.1M$7.1MFY2023FY2024: $9.7M$9.7MFY2024FY2025: $4.0M$4.0MFY2025

From CRVO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
Mar 16
Estimated date · After the close
Reported EPS
-$0.39
Quarter ended Sep 2026
Year ago EPS
-$0.84
Same quarter last year
Revenue
$0
−100.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.80Dec '24Mar 2025: -$0.56Mar '25Jun 2025: -$0.70Jun '25Sep 2025: -$0.84Sep '25Dec 2025: -$0.88Dec '25Mar 2026: -$0.86Mar '26Jun 2026: -$0.64Jun '26Sep 2026: -$0.39Sep '26Latest -$0.39
Revenue by quarter
Dec 2024: $2.2MDec '24Mar 2025: $1.9MMar '25Jun 2025: $1.8MJun '25Sep 2025: $322,569Sep '25Dec 2025: $8,726Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How CRVO moved after its last 8 reports
Average move the session after a report ±4.1%
Nov 9, 2026After the close−4.2%
Aug 10, 2026After the close+8.0%
May 18, 2026After the close−4.9%
Mar 17, 2026After the close−6.4%
Nov 10, 2025After the close+1.0%
Aug 11, 2025Time not announced−3.5%
May 12, 2025After the close−4.4%
Mar 18, 2025After the close+0.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CRVOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CRVO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CRVO

Technical Analysis

CRVO · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 13% below its 20 day and 53% below its 50 day average. It is 118% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 37), near oversold. The nearest support is the Pivot S1 at $1.36, and the nearest resistance the Pivot at $1.50.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNear oversold
VolatilityHigh, 15.9%/day
Key levels
$10.0052 week high+584.9%
$3.19200 day average+118.5%
$2.53100 day average+73.3%
$2.2450 day average+53.4%
$2.20Swing high (Nov 12)+50.7%
$1.6620 day average+13.7%
$1.61Pivot R1+10.3%
$1.50Pivot+2.7%
$1.46Last close
$1.36Pivot S1−6.8%
$1.2752 week low−13.0%
$1.27Swing low (Nov 6)−13.0%
Indicators
RSI (14)37.30Weak, oversold below 30Neutral
MACD-0.23Above its signal lineBullish
Stochastic15.4Near the bottom of its rangeOversold
ADX (14)24.8Weak trend
Williams %R-79.6Oversold below −80, overbought above −20Neutral
CCI (20)-56.4Oversold below −100, overbought above 100Neutral
Rate of change+2.8%Change over 10 sessionsBullish
ATR (14)$0.23Typical daily range, 15.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CRVO

What happened before

See how CRVO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CRVO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CRVO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CRVOHow many large options trades hit CRVO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CRVO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼11 buying vs 19 selling
  • ▼Held by funds -2.8 pts
  • ▼Funds holding -1
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3637−2.7%
In funds' top 10110.0%
Held by funds8.8%11.6%−2.8 pts
New / increased3 / 87 / 9−31.3%
Reduced / sold out14 / 58 / 5+46.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CRVO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CRVO Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$3.2M2 buys · 2 insiders
Sold$00 sales · 0 insiders
2026-06 bought $3.0M2026-11 bought $153KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18John J AlamCEO & PresidentBuy100,000$1.53$153K
Jun 11Joshua S BogerDirectorBuy955,414$3.14$3.0M
Nov 18, 2025William Robert ElderCFO, GC & SecretaryBuy3,500$8.36$29K
Nov 18, 2025Matthew WintonChief Commercial and BusinessBuy5,000$8.29$41K
Nov 17, 2025John J AlamCEO & PresidentBuy21,600$8.46$183K
Nov 17, 2025Sylvie GregoireDirectorBuy21,600$8.46$183K
Every insider buy and sale for CRVO over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CRVO insider trades →

From SEC Form 4 filings by CRVO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRVO is in one of them and how their past CRVO trades turned out.

CRVO in the AI portfolios
Loading…

CRVO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CRVO in an article yet. Here's the latest on the wider market.

CRVO in the news

About CervoMed

CervoMed is a biotechnology company based in Boston, Massachusetts, that is developing treatments for brain disorders linked to aging. Its lead candidate, neflamapimod, is an oral drug designed to reduce brain inflammation and address problems with communication between nerve cells. The drug is in clinical trials for dementia with Lewy bodies and is also being studied for other neurological conditions, including ALS. The company does not yet have an approved product, and its intended users are patients with these conditions.

Headquarters
Boston, MA